Orion Laboratories, L.L.C.

Orion Laboratories, L.L.C. was paid $4.41M by Medicaid between Jan 2020 and Dec 2024, across 106 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 25% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Louisiana

Rank by total paid#14 of 66

Median peer was paid$253K

This provider vs. median17×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	47,150	$1.14M
2021	34,579	$895K
2022	32,487	$491K
2023	61,923	$726K
2024incomplete	101,238	$1.16M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	25%	28,372	11,532	$1.11M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	25%	49,522	18,882	$1.11M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	12%	20,307	8,777	$546K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	5.3%	16,841	12,840	$233K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	5.3%	16,816	12,819	$233K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	4.6%	15,334	11,637	$203K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	3.9%	2,715	2,050	$174K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	3.3%	2,244	1,617	$146K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	2.5%	3,941	3,654	$109K
80050	General health panel	2.0%	6,910	5,607	$89K
80074		1.8%	5,382	4,135	$77K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	3,640	3,092	$36K

94 more codes

80061	Lipid panel	<1%	6,298	$28K
86708		<1%	4,424	$24K
86706		<1%	4,518	$23K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,612	$21K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,165	$20K
86703		<1%	4,657	$20K
87086	Culture, bacterial; quantitative colony count, urine	<1%	6,108	$16K
86780		<1%	2,974	$16K
87563		<1%	1,063	$10K
83735		<1%	3,822	$10K
84481		<1%	2,054	$8K
80053	Comprehensive metabolic panel	<1%	3,553	$8K
84439		<1%	2,595	$7K
86592		<1%	4,362	$7K
82607		<1%	1,185	$7K
83036	Hemoglobin; glycosylated (A1C)	<1%	3,189	$7K
87529		<1%	309	$7K
82746		<1%	979	$6K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	669	$6K
87186		<1%	1,383	$5K
36415	Collection of venous blood by venipuncture	<1%	9,862	$5K
86803		<1%	812	$5K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	2,243	$4K
83970		<1%	504	$4K
84403		<1%	390	$4K
85027		<1%	4,068	$4K
87077		<1%	1,355	$4K
87070		<1%	1,107	$4K
82670		<1%	285	$4K
84443	Thyroid stimulating hormone (TSH)	<1%	1,298	$3K
84402		<1%	269	$3K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	76	$3K
84270		<1%	276	$2K
80069		<1%	1,495	$2K
81015		<1%	2,187	$2K
84146		<1%	257	$2K
83001		<1%	248	$2K
83002		<1%	248	$2K
81025		<1%	671	$2K
86769		<1%	63	$2K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	20	$2K
81001		<1%	2,866	$2K
82248		<1%	938	$1K
84144		<1%	154	$1K
84153		<1%	409	$1K
86376		<1%	169	$1K
80048	Basic metabolic panel (calcium, ionized)	<1%	1,092	$1K
82728		<1%	408	$990.94
84703		<1%	310	$971.94
87075		<1%	317	$940.66
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	60	$840.91
87205		<1%	555	$832.44
83090		<1%	231	$822.34
82951		<1%	129	$650.58
84460		<1%	174	$623.17
85014		<1%	438	$606.55
85018		<1%	436	$606.51
84450		<1%	170	$602.69
80164		<1%	215	$598.34
82627		<1%	62	$566.30
83540		<1%	542	$531.13
82570		<1%	515	$500.31
86140		<1%	324	$481.21
82533		<1%	62	$442.12
84100		<1%	272	$442.10
84436		<1%	621	$413.50
83550		<1%	316	$403.85
82977		<1%	100	$391.72
83525		<1%	89	$361.06
82043		<1%	276	$356.69
80184		<1%	70	$247.19
84156		<1%	439	$239.93
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	626	$232.29
85652		<1%	203	$221.36
82150		<1%	58	$206.56
85651		<1%	164	$203.90
84480		<1%	493	$201.32
83690		<1%	59	$196.62
84134		<1%	145	$128.07
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	65	$105.56
83721		<1%	100	$102.42
82550		<1%	211	$86.52
87340		<1%	18	$86.35
84550		<1%	48	$37.55
85610		<1%	50	$30.11
82247		<1%	17	$21.01
85007		<1%	240	$17.62
85049		<1%	49	$6.78
85048		<1%	232	$5.06
85041		<1%	48	$3.37
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	453	$0.00
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	0%	994	$0.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	2,607	$0.00
99999		0%	61	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSLAUGHTER, DAVID (CHIEF EXECUTIVE OFFICER)